M&A Deal Summary |
|
|---|---|
| Date | 2015-08-27 |
| Target | MB2 |
| Sector | Life Science |
| Buyer(s) | Novo Nordisk A/S |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1925 |
| Sector | Life Science |
| Employees | 39,062 |
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. Company has experience and capabilities that enable to help people defeat other serious chronic conditions, haemophilia, growth disorders and obesity.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 6 |
| Sector (Life Science) | 2 of 6 |
| Type (Add-on Acquisition) | 2 of 6 |
| State (Indiana) | 2 of 2 |
| Country (United States) | 2 of 5 |
| Year (2015) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-08-27 |
Calibrium
Indianapolis, Indiana, United States Calibrium LLC is a biopharmaceutical company focused on the discovery and early development of novel peptides for the treatment of diabetes and related metabolic diseases. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-08-17 |
Ziylo
Bristol, United Kingdom Ziylo is a supramolecular chemistry company that has developed a third 'biomimetic' class of glucose binding molecules (GBMs). These molecules have potential to be a critical component in medical devices such as Continuous Glucose Monitors (CGM) and therapeutics such as Glucose Responsive Insulins (GRIs). Ziylo was founded in 2014 and is based in Bristol, United Kingdom. |
Buy | $800M |
